Log in

NASDAQ:TXMD - TherapeuticsMD Stock Price, Forecast & News

$2.48
-0.08 (-3.13 %)
(As of 01/27/2020 07:20 AM ET)
Today's Range
$2.42
Now: $2.48
$2.58
50-Day Range
$2.26
MA: $2.39
$2.81
52-Week Range
$1.82
Now: $2.48
$6.09
Volume2.87 million shs
Average Volume3.43 million shs
Market Capitalization$672.53 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66
TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TXMD
Previous SymbolNYSEMKT:TXMD
CUSIPN/A
Phone561-961-1900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.10 million
Book Value$0.41 per share

Profitability

Net Income$-132,620,000.00
Net Margins-427.70%

Miscellaneous

Employees241
Market Cap$672.53 million
Next Earnings Date2/20/2020 (Estimated)
OptionableOptionable

Receive TXMD News and Ratings via Email

Sign-up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.


TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD Inc (NASDAQ:TXMD) posted its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.06. The business earned $8.21 million during the quarter, compared to analyst estimates of $8.05 million. TherapeuticsMD had a negative return on equity of 430.28% and a negative net margin of 427.70%. The business's revenue was up 136.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.16) earnings per share. View TherapeuticsMD's Earnings History.

When is TherapeuticsMD's next earnings date?

TherapeuticsMD is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for TherapeuticsMD.

What price target have analysts set for TXMD?

9 brokerages have issued twelve-month target prices for TherapeuticsMD's shares. Their forecasts range from $3.00 to $17.00. On average, they expect TherapeuticsMD's stock price to reach $9.11 in the next year. This suggests a possible upside of 267.4% from the stock's current price. View Analyst Price Targets for TherapeuticsMD.

What is the consensus analysts' recommendation for TherapeuticsMD?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD.

Has TherapeuticsMD been receiving favorable news coverage?

Headlines about TXMD stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TherapeuticsMD earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for TherapeuticsMD.

Are investors shorting TherapeuticsMD?

TherapeuticsMD saw a increase in short interest in January. As of January 15th, there was short interest totalling 86,820,000 shares, an increase of 9.4% from the December 31st total of 79,360,000 shares. Based on an average daily volume of 3,670,000 shares, the days-to-cover ratio is currently 23.7 days. Currently, 36.6% of the company's shares are short sold. View TherapeuticsMD's Current Options Chain.

Who are some of TherapeuticsMD's key competitors?

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include Opko Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Cleveland-Cliffs (CLF), CannTrust (CNTTF), NVIDIA (NVDA), Horizon Therapeutics (HZNP), bluebird bio (BLUE), Global Blood Therapeutics (GBT) and Novavax (NVAX).

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the folowing people:
  • Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 48)
  • Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 57)
  • Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 51)
  • Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 61)
  • Mr. Mitchell L. Krassan, Exec. VP & Chief Strategy Officer (Age 53)

Who are TherapeuticsMD's major shareholders?

TherapeuticsMD's stock is owned by a number of of institutional and retail investors. Top institutional investors include Sanders Morris Harris LLC (0.14%) and Janney Montgomery Scott LLC (0.05%). Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Daniel A Cartwright, Group L P Column, Jane F Barlow, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD.

Which institutional investors are selling TherapeuticsMD stock?

TXMD stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC. View Insider Buying and Selling for TherapeuticsMD.

Which institutional investors are buying TherapeuticsMD stock?

TXMD stock was purchased by a variety of institutional investors in the last quarter, including Janney Montgomery Scott LLC. Company insiders that have bought TherapeuticsMD stock in the last two years include Angus C Russell, Brian Bernick, Group L P Column, Jane F Barlow, John CK Iv Milligan, Robert G Finizio and Tommy G Thompson. View Insider Buying and Selling for TherapeuticsMD.

How do I buy shares of TherapeuticsMD?

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is TherapeuticsMD's stock price today?

One share of TXMD stock can currently be purchased for approximately $2.48.

How big of a company is TherapeuticsMD?

TherapeuticsMD has a market capitalization of $672.53 million and generates $16.10 million in revenue each year. The company earns $-132,620,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. TherapeuticsMD employs 241 workers across the globe.View Additional Information About TherapeuticsMD.

What is TherapeuticsMD's official website?

The official website for TherapeuticsMD is http://www.therapeuticsmd.com/.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at 561-961-1900 or via email at [email protected]


MarketBeat Community Rating for TherapeuticsMD (NASDAQ TXMD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  334 (Vote Outperform)
Underperform Votes:  291 (Vote Underperform)
Total Votes:  625
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel